Medpace Holdings, Inc. (MEDP)

Clinical research organization, 46 countries. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 10, 2026. Ranked 93 of the 104 Healthcare companies read so far, by the share within reach now.

Medpace’s approximately 6,200 employees across 46 countries run clinical trials for drug developers, read as one scientific research and development services pattern.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 17% now, 42% at the end of 2027, 57% at the end of 2028, 66% at the end of 2030. By the patterns, the work is about 67% desk work, 17% people work and 16% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 33% of the working time stays with people (conversation, in-person and hands-on work), 51% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

6,200 employees as of December 31, 2025 (stated). The filing counts no employees by country; employees are in 46 countries.

The filing: “As of December 31, 2025 we had approximately 6,200 employees located across 46 countries.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 6,200 employees across 46 countries, 5,900 a year earlier; about 66% women; no U.S. employees under a collective bargaining agreement; 75% of newly filled management roles filled from within.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Scientific Research and Development Services, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• IQVIA Holdings Inc. (IQV, 93,000 employees)22% now, 62% by 2028
• Charles River Laboratories International, Inc. (CRL, 19,700 employees)17% now, 55% by 2028
• Fortrea Holdings Inc. (FTRE, 14,300 employees)17% now, 57% by 2028

What the filing says about AI

7 sentences in the filing name AI. The filing names AI seven times, as risks: insufficient oversight of AI in operations, and falling behind competitors’ AI investment.

• “Continued evolution and use of machine learning and generative artificial intelligence ("AI"), including risks arising from insufficient human oversight of AI or a lack of controls and procedures monitoring the use of AI in day-to-day operations as well as from potential future competitive disadvantages related to a lack of investment in AI tools, could have a negative impact on our financial r...”
• “If we do not keep pace with rapid technological changes, including AI, our services may become less competitive or obsolete.”
• “Continued evolution and use of machine learning and generative artificial intelligence ("AI"), including risks arising from insufficient human oversight of AI or a lack of controls and procedures monitoring the use of AI in day-to-day operations as well as from potential future competitive disadvantages related to a lack of investment in AI tools, could have a negative impact on our financial r...”
• “The development, adoption, and use for generative AI technologies are still in their early stages and ineffective or inadequate AI development or deployment practices by the Company or third-party developers or vendors could result in unintended consequences.”
• “Developing, testing, and deploying resource-intensive AI systems may require additional investment and increase our costs.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20235median 1
• Fiscal 20247median 4
• Fiscal 20257median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by function or country; one research services pattern by description.

Source: the company's annual report on EDGAR, accession 0001668397-26-000006, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.